Borrelia burgdorferi BBK32 Inhibits the Classical Pathway by Blocking Activation of the C1 Complement Complex.

Pathogens that traffic in blood, lymphatics, or interstitial fluids must adopt strategies to evade innate immune defenses, notably the complement system. Through recruitment of host regulators of complement to their surface, many pathogens are able to escape complement-mediated attack. The Lyme dise...

Full description

Bibliographic Details
Main Authors: Brandon L Garcia, Hui Zhi, Beau Wager, Magnus Höök, Jon T Skare
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS Pathogens
Online Access:http://europepmc.org/articles/PMC4725857?pdf=render
id doaj-7b0d19db8f324f1ba8dbf2435479457d
record_format Article
spelling doaj-7b0d19db8f324f1ba8dbf2435479457d2020-11-24T21:52:47ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742016-01-01121e100540410.1371/journal.ppat.1005404Borrelia burgdorferi BBK32 Inhibits the Classical Pathway by Blocking Activation of the C1 Complement Complex.Brandon L GarciaHui ZhiBeau WagerMagnus HöökJon T SkarePathogens that traffic in blood, lymphatics, or interstitial fluids must adopt strategies to evade innate immune defenses, notably the complement system. Through recruitment of host regulators of complement to their surface, many pathogens are able to escape complement-mediated attack. The Lyme disease spirochete, Borrelia burgdorferi, produces a number of surface proteins that bind to factor H related molecules, which function as the dominant negative regulator of the alternative pathway of complement. Relatively less is known about how B. burgdorferi evades the classical pathway of complement despite the observation that some sensu lato strains are sensitive to classical pathway activation. Here we report that the borrelial lipoprotein BBK32 potently and specifically inhibits the classical pathway by binding with high affinity to the initiating C1 complex of complement. In addition, B. burgdorferi cells that produce BBK32 on their surface bind to both C1 and C1r and a serum sensitive derivative of B. burgdorferi is protected from killing via the classical pathway in a BBK32-dependent manner. Subsequent biochemical and biophysical approaches localized the anti-complement activity of BBK32 to its globular C-terminal domain. Mechanistic studies reveal that BBK32 acts by entrapping C1 in its zymogen form by binding and inhibiting the C1 subcomponent, C1r, which serves as the initiating serine protease of the classical pathway. To our knowledge this is the first report of a spirochetal protein acting as a direct inhibitor of the classical pathway and is the only example of a biomolecule capable of specifically and noncovalently inhibiting C1/C1r. By identifying a unique mode of complement evasion this study greatly enhances our understanding of how pathogens subvert and potentially manipulate host innate immune systems.http://europepmc.org/articles/PMC4725857?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Brandon L Garcia
Hui Zhi
Beau Wager
Magnus Höök
Jon T Skare
spellingShingle Brandon L Garcia
Hui Zhi
Beau Wager
Magnus Höök
Jon T Skare
Borrelia burgdorferi BBK32 Inhibits the Classical Pathway by Blocking Activation of the C1 Complement Complex.
PLoS Pathogens
author_facet Brandon L Garcia
Hui Zhi
Beau Wager
Magnus Höök
Jon T Skare
author_sort Brandon L Garcia
title Borrelia burgdorferi BBK32 Inhibits the Classical Pathway by Blocking Activation of the C1 Complement Complex.
title_short Borrelia burgdorferi BBK32 Inhibits the Classical Pathway by Blocking Activation of the C1 Complement Complex.
title_full Borrelia burgdorferi BBK32 Inhibits the Classical Pathway by Blocking Activation of the C1 Complement Complex.
title_fullStr Borrelia burgdorferi BBK32 Inhibits the Classical Pathway by Blocking Activation of the C1 Complement Complex.
title_full_unstemmed Borrelia burgdorferi BBK32 Inhibits the Classical Pathway by Blocking Activation of the C1 Complement Complex.
title_sort borrelia burgdorferi bbk32 inhibits the classical pathway by blocking activation of the c1 complement complex.
publisher Public Library of Science (PLoS)
series PLoS Pathogens
issn 1553-7366
1553-7374
publishDate 2016-01-01
description Pathogens that traffic in blood, lymphatics, or interstitial fluids must adopt strategies to evade innate immune defenses, notably the complement system. Through recruitment of host regulators of complement to their surface, many pathogens are able to escape complement-mediated attack. The Lyme disease spirochete, Borrelia burgdorferi, produces a number of surface proteins that bind to factor H related molecules, which function as the dominant negative regulator of the alternative pathway of complement. Relatively less is known about how B. burgdorferi evades the classical pathway of complement despite the observation that some sensu lato strains are sensitive to classical pathway activation. Here we report that the borrelial lipoprotein BBK32 potently and specifically inhibits the classical pathway by binding with high affinity to the initiating C1 complex of complement. In addition, B. burgdorferi cells that produce BBK32 on their surface bind to both C1 and C1r and a serum sensitive derivative of B. burgdorferi is protected from killing via the classical pathway in a BBK32-dependent manner. Subsequent biochemical and biophysical approaches localized the anti-complement activity of BBK32 to its globular C-terminal domain. Mechanistic studies reveal that BBK32 acts by entrapping C1 in its zymogen form by binding and inhibiting the C1 subcomponent, C1r, which serves as the initiating serine protease of the classical pathway. To our knowledge this is the first report of a spirochetal protein acting as a direct inhibitor of the classical pathway and is the only example of a biomolecule capable of specifically and noncovalently inhibiting C1/C1r. By identifying a unique mode of complement evasion this study greatly enhances our understanding of how pathogens subvert and potentially manipulate host innate immune systems.
url http://europepmc.org/articles/PMC4725857?pdf=render
work_keys_str_mv AT brandonlgarcia borreliaburgdorferibbk32inhibitstheclassicalpathwaybyblockingactivationofthec1complementcomplex
AT huizhi borreliaburgdorferibbk32inhibitstheclassicalpathwaybyblockingactivationofthec1complementcomplex
AT beauwager borreliaburgdorferibbk32inhibitstheclassicalpathwaybyblockingactivationofthec1complementcomplex
AT magnushook borreliaburgdorferibbk32inhibitstheclassicalpathwaybyblockingactivationofthec1complementcomplex
AT jontskare borreliaburgdorferibbk32inhibitstheclassicalpathwaybyblockingactivationofthec1complementcomplex
_version_ 1725874957077970944